Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

Annual report 2018 (pdf):
Abstract (in Norwegian)
Download in single page format - double page (broad) format

Publication overview

Current news and events

Institute Seminar Wednesday August 21st 12:00:Viola Lobert

Viola Lobert

The first Institute Seminar for the autumn season of 2019 will take place Wednesday August 21st at 12:00 in the auditorium in the Research Building, Montebello.

The speaker is Viola Lobert, PhD, Scientist in the research group of Tor Erik Rusten, Department of Molecular Cell Biology.

Title of her talk: Targeting ion transport to prevent metastasis in mucinous colorectal cancer

New insights into the molecular mechanism underlying a human developmental disorder published in Cell Reports

Kari-Anne M Frikstad (first author) and Sebastian Patzke (lead author). Photo: Terje Heiestad

In a recent publication in the journal Cell Reports, Kari-Anne M Frikstad, in team with six international collaborators and her co-workers in Sebastian Patzke's project group at the Institute for Cancer Research, provides new insights on how cells build a functional antenna for sensation of a key developmental signaling pathway required for normal brain development.  

Yan Zhen identifies mechanism of autophagosome closure

Yan Zhen

In a recent paper in the journal Autophagy, Dr. Yan Zhen and her co-workers in Harald Stenmark's group at Institute for Cancer Research and Centre for Cancer Cell Reprogramming (CanCell) show a mechanism for how autophagosomes are sealed, a crucial step in autophagy.

Jan Terje Andersen head of hiv research program receiving 19 mill NOK

Jan Terje Andersen

A consortium of University of Oslo, The International AIDS Vaccine Initiative (IAVI) and the Translational Health Science and Technology Institute (THSTI) has been granted 19.09 MNOK (about U.S. $2.2M) for a period of three years from the Research Council of Norway through the GLOBVAC (Global Health Vaccination and Research) program for the development of broadly neutralizing antibodies as HIV prevention products.

Units and subpages

View all subunitsHide all subunits